Isotype selection for antibody-based cancer therapy

Natasa Vukovic, Andrea van Elsas, J. Sjef Verbeek, Dietmar M. W. Zaiss

Research output: Contribution to journalReview articlepeer-review

Abstract / Description of output

The clinical application of monoclonal antibodies (mAbs) revolutionised the field of cancer therapy as it enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play a role in the anti-tumour effect of mAbs. These include blocking of tumour-specific growth factor receptors but also complement and cell-mediated tumour cell lysis. Thus, for many mAbs Fc-mediated effector functions critically contribute to the efficacy of treatment. As Ig isotypes differ in their ability to bind to FcRs on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Considering that clinical efficacy of many mAbs is currently achieved only in subsets of patients, optimal isotype selection and Fc optimisation during antibody development may represent an important step towards improved patient outcome. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc-engineering strategies to improve mAbs application.
Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalClinical & Experimental Immunology
Early online date5 Nov 2020
Publication statusE-pub ahead of print - 5 Nov 2020

Keywords / Materials (for Non-textual outputs)

  • mAbs
  • isotype
  • Fc tail
  • effector functions
  • cancer


Dive into the research topics of 'Isotype selection for antibody-based cancer therapy'. Together they form a unique fingerprint.

Cite this